A sporadic PVOD patient with confirmed biallelic EIF2AK4 mutations displayed an atypical treatment response to PAH‐targeted drugs, suggesting genetic heterogeneity in PVOD [136]. The gene discussed is EIF2AK4; the disease is pulmonary venoocclusive disease.